FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response: 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person [*]					2. Issuer Name and Ticker or Trading Symbol <u>ICU MEDICAL INC/DE</u> [ICUI]									5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director X 10% Owner							
(Last) (First) (Middle) 951 CALLE AMANECER					3. Date of Earliest Transaction (Month/Day/Year) 05/17/2011									X		er (give title		Other (spec below)		specify	
(Street) SAN CLEME (City)	NTE C.	92673 Zip)	4. If A										 Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person 								
Table I - Non-Deri 1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)				Ative Securitie 2A. Deemed Execution Date, if any (Month/Day/Year)			3. Tra Coo	cquired	4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and				A) or	5. A See Be Ow	Amoun curities eneficial vned	ntof 6.Own s Form: lly (D)or Indirec		Direct India Bene ct (I) Own		lature of irect reficial nership	
								le V	Ar	nount	(A) or (D)	Price		Following Reported Transaction(s) (Instr. 3 and 4)			(Instr. 4)		(Instr. 4)		
Common	Stock	05/17/2011	05/17/2011		2	۲	(6,500	Α	\$14.625		340,419		D							
Common Stock			05/17/2011	05/17/2011		S	1)		6,500	D	\$42.4818 ⁽²⁾		333,919		D						
Common Stock													1,186,843		Ι		by Part	nership ⁽³⁾			
		Та	able II - Deriva (e.g., p					· ·		posed o , convei					wned						
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date E Expiratio (Month/D	n D		Am Sec Und Der Sec	7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)		9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s (Instr. 4)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		11. Nature of Indirect Beneficial Ownership (Instr. 4)	
				Code	v	(A)	(D)	Date Exercisat	ole	Expiratio Date	n Titl	e	Amount or Number of Shares								
Non- Qualified Stock Option (right to buy)	\$14.625	05/17/2011	05/17/2011	x			6,500	09/09/200	03	09/09/201		nmon tock	6,500		(4)	186	,000	D			

Explanation of Responses:

1. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person on March 7, 2011.

2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$42.34 to \$42.77, inclusive. The reporting person undertakes to provide ICU Medical, Inc., any security holder of ICU Medical, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.

3. Common Stock owned by George A. Lopez M.D. Second Family Limited Partnership. Dr. Lopez holds a one-percent general partnership interest in the Partnership. As general partner, he has the power to vote and power to dispose of the 1,186,843 shares owned by the Partnership and may be deemed to be beneficial owner of such shares. The Partnership acquired the shares on 2/24/99 from Trusts for the benefit of the Lopez children, the Christopher George Lopez Children's Trust and the Nicholas George Lopez Children's Trust, which own a 99% limited partnership in the Partnership. Dr. Lopez is not trustee of and has no interest in the children's Trusts. Except to the extent of his undivided one percent general partnership interest in the assets of the Partnership. Dr. Lopez disclaims any beneficial ownership of the shares on the shares on the extent of his undivided one percent general partnership interest in the assets of the Partnership. Dr. Lopez disclaims any beneficial ownership of the shares of the Partnership.

4. Transaction is the exercise of a derivative security; see Column 2.

<u>By: Lynn DeMartini For:</u> <u>George A. Lopez, M.D.</u>

05/17/2011

Date

** Signature of Reporting Person

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

 * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.